Levi & Korsinsky is investigating the Board of Directors of QuadraMed Corp. (“QuadraMed” or the “Company”) (NasdaqGM: QDHC) for possible breaches of fiduciary duty and other violations of state law in connection with their attempt to sell the Company to private equity firm Francisco Partners. Under the terms of the deal, Francisco Partners will acquire all outstanding shares of QuadraMed common stock for $8.50 per share and the Series A Cumulative Mandatory Convertible Preferred Stock for $13.7097 per share, for a total transaction value of approximately $126 million.

The investigation concerns whether the QuadraMed Board of Directors breached their fiduciary duties to QuadraMed shareholders given that the offer price is only a small premium over the $7.94 price the Company's shares traded at as recently as October 14, 2009 and at least one analyst set a price target for QuadraMed stock at $11.00 per share.

If you own common stock in QuadraMed and wish to obtain additional information, please contact us at the number listed below or visit http://www.zlk.com/qdhc1.html.

Levi & Korsinsky has expertise in prosecuting investor securities litigation and extensive experience in actions involving financial fraud and represents investors throughout the nation, concentrating its practice in securities and shareholder litigation.

Grafico Azioni Quadramed Corp (MM) (NASDAQ:QDHC)
Storico
Da Mag 2024 a Giu 2024 Clicca qui per i Grafici di Quadramed Corp (MM)
Grafico Azioni Quadramed Corp (MM) (NASDAQ:QDHC)
Storico
Da Giu 2023 a Giu 2024 Clicca qui per i Grafici di Quadramed Corp (MM)